

Indivior – Q3 2022 Fact Sheet





Forward-Looking Statements

Statements included in this presentation that are not a description of historical facts are forward-looking statements. Words or phrases such as “believe,” “may,” “could,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “seek,” “plan,” “expect,” “should,” “would” or similar expressions are intended to identify forward-looking statements and are based on our current beliefs and expectations. These forward-looking statements include, without limitation, statements regarding the proposed acquisition of Opiant Pharmaceuticals Inc. (“Opiant”), the expected timetable for completing the transaction, future financial and operating results, benefits and synergies of the transaction, future opportunities for the combined businesses and any other statements regarding events or developments that we believe or anticipate will or may occur in the future. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements. These factors include risks and uncertainties related to, among other things: uncertainties as to the timing of the proposed merger; the possibility that competing acquisition proposals will be made; the inability to complete the proposed merger due to the failure to obtain Opiant’s stockholder adoption of the merger agreement or the failure to satisfy other conditions to completion of the proposed merger, including required regulatory clearances or approvals; the potential that the expected benefit and opportunities of the transaction, if completed, may not be realized or may take longer to realize than expected; the risk that OPNT003 does not receive FDA approval in the expected timeline, or at all; the risk that one approved, OPNT003 may not reach the revenue anticipate due to competition, product uptake or pricing or due to labeling or regulatory restrictions, challenges inherent in product research and development, including uncertainty of clinical successes and obtaining regulatory approval and challenges to patents; the failure of the transaction to close for any other reason; the effects of disruption caused by the transaction making it more difficult to maintain relationships with employees, collaborators, customers, vendors and other business partners; the risk that stockholder litigation in connection with the proposed merger may result in significant delay or costs of defense, indemnification and liability; diversion of management’s attention from ongoing business concerns and other risks and uncertainties that may affect future results of the combined company, including the risks described in Indivior’s Annual Report and Accounts 2021 and press releases and filings since that time, including Indivior’s press release of November 14, 2022 and Opiant’s Annual Report on Form 10-K for the year ended December 31, 2021 and Quarterly Reports on Form 10-Q for the quarters ended March 31, 2022, and June 30, 2022. All forward-looking statements are qualified in their entirety by this cautionary statement and neither Indivior or Opiant undertake any obligation to revise or update this report to reflect events or circumstances after the date hereof, except as required by law.

Important Information for Investors and stockholders

This communication does not constitute a solicitation of any vote or approval. Opiant intends to file with the SEC and mail to its stockholders a definitive proxy statement in connection with the proposed transactions. OPIANT’S STOCKHOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT OPIANT AND THE PROPOSED MERGER. Investors and stockholders may obtain copies of the proxy statement and other documents filed with the SEC by Opiant (when they became available) free of charge from the SEC’s website at www.sec.gov or by accessing Opiant’s website at www.opiant.com. Copies of the documents filed with the SEC by Indivior (when they become available) may be obtained free of charge from the SEC’s website at www.sec.gov or by accessing Indivior’s website at www.indivior.com.

Participants in the merger solicitation

Indivior, Opiant, and certain of their directors, executive officers and employees may be considered participants in the solicitation of proxies from Opiant’s stockholders with respect to the proposed transactions. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of Opiant’s stockholders in connection with the proposed merger and a description of their direct and indirect interests, by security holdings or otherwise, will be set forth in the definitive proxy statement that Opiant intends to file with the SEC when it becomes available. Information about Indivior’s directors and executive officers is set forth in Indivior’s Annual Report and Accounts 2021 available at www.indivior.com. Information about Opiant’s directors and executive officers is set forth in Opiant’s definitive proxy statement for its 2022 Annual Meeting of Stockholders, which was filed with the SEC on April 18, 2022. These documents may be obtained as indicated above.

- Global leader in addiction treatment and science with strong growth prospects and solid balance sheet
- Proposed acquisition of Opiant Pharmaceuticals (NASDAQ: OPNT) to strengthen addiction leadership
- Additional listing in the US targeted for Spring 2023


Key Facts

Symbol:	INDV (LSE)
52-wk. high:	1,837 (GBP)
52-wk. low:	1,052 (GBP)
Market cap:	\$3.0 bil. (US\$)
Cash¹ 3Q'22:	\$1.0 bil.+ (US\$)
LT Debt 3Q'22	\$237 mil. (US\$)
Fiscal YE:	December
Headquarters:	Richmond, VA
Employees:	~900

Note: Market data as of December 15, 2022

Q3 2022 Net Revenue

(Sep 30, 2022)



+24% Q3 2022 net revenue growth

\$58m Q3 2022 adj. op. profit¹

\$1.0b² Gross cash & Investments at Q3 2022

\$100m Share buyback announced Q1 2022

¹ Excludes Exceptional Items

² See discussion of obligations in Note 9 and 10, including our term debt and other payment obligations from Q3 2022 Results press release dated October 27, 2022

Leadership

Graham Hetherington
Chair

Mark Crossley
Chief Executive Officer

Ryan Preblick
Chief Financial Officer

Investor Relations

Jason Thompson
Jason.Thompson@Indivior.com
Tel: +804-402-7123

Tim Owens
Timothy.Owens@Indivior.com
Tel: +804-263-3978


Who We Are

Indivior is the global leader in medication-assisted treatment for opioid use disorder (OUD), which has worsened during COVID, and has held the number one position in the largest market (US) for over 15 years. The Company also has a strong international presence, serving OUD patients in 39 countries.

We are leveraging our historic strength in OUD medications, proprietary extended-release delivery platform, strong cash flow generation and balance sheet strength to continue growing our treatment options for addiction.

12 Month-ending Reported Provisional Number of Drug Overdose Deaths by Drug or Drug Class (CDC data)


(May 2019 - May 2022)



Indivior Approved Products

SUBLOCADE® (buprenorphine extended-release) injection is a once-monthly subcutaneous injection for the treatment of moderate to severe OUD. Indivior is targeting a >\$1.5 bil. potential annual peak net revenue opportunity.

SUBLOCADE® Total Annual NR Growth is Strong



PERSERIS® (risperidone) extended-release injection is a once-monthly subcutaneous injection for schizophrenia. Indivior is targeting an annual peak net revenue opportunity of \$200-\$300 million.

SUBOXONE® (buprenorphine and naloxone) Film and **SUBUTEX®** (buprenorphine) tablet also are used to treat OUD and are taken daily by sublingual administration. These treatments are available in key global markets.

SUBOXONE® is not promoted in US Market; SUBLOCADE®, PERSERIS® and SUBUTEX® are registered trademarks of Indivior UK Limited